pixantrone has been researched along with Local Neoplasm Recurrence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Deuster, O; Dreyling, MH; Ernst, T; Frontzek, F; Hess, G; Hüttmann, A; Keller, U; Lenz, G; Marks, R; Pott, C; Rosenwald, A; Ruckes, C; Theobald, M; Trautmann, M; Viardot, A; Witzens-Harig, M | 1 |
| Coiffier, B; Egorov, A; Pettengell, R; Singer, J; Sivcheva, L | 1 |
| Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M | 1 |
| Andorsky, D; Beck, JT; Belada, D; Dakhil, S; Daly, R; Dean, JP; Failloux, N; Georgiev, P; Hübel, K; Inhorn, LF; Pavlyuk, M; Pettengell, R; Quick, D | 1 |
| Borchmann, P; Camboni, G; Engert, A; Gisselbrecht, C; Günther, H; Harousseau, JL; Morschhauser, F; Parry, A; Pfreundschuh, DM; Rudolph, C; Schnell, R; Wilhelm, M | 1 |
| Allievi, C; Bernareggi, A; Cabanillas, F; Fayad, L; Laffranchi, B; Levine, AM; Lim, ST; Modiano, M; Tulpule, A | 1 |
5 trial(s) available for pixantrone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome | 2022 |
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.
Topics: Adult; Aged; Europe; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome | 2018 |
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Research Design; Rituximab | 2016 |
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome | 2003 |
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
1 other study(ies) available for pixantrone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous | 2019 |